Fig. 3

Identification of targeted MAPs in Mlh1^+/+ and Mlh1^-/- tumor cells. A The peptide list generated from RNAseq analysis of CT26 Mlh1^+/+ cells grown in vitro was compared to the corresponding lists obtained after tumor growth in mice (see Table 2). Thus, peptides lost after injection in CT26 Mlh1^+/+ post BALB/c M3 mouse and retrieved after inoculation in CT26 Mlh1^+/+ post NOD-SCID M2 mouse were selected. The overlap of these two peptide datasets generated the database of CT26 Mlh1^+/+ targeted peptides. B Peptide lists generated from RNAseq analysis in Mlh1^-/- samples before and after in vivo growth were compared (see Table 2). This allowed the identification of peptides lost after injection in CT26 Mlh1^-/- post BALB/c M2, M6, and M7 mice but maintained in CT26 Mlh1^-/- post NOD-SCID M5 mouse. The overlap of these two datasets generated a list of peptides from which specific CT26 Mlh1^+/+ sequences were removed. The latter list created the targeted peptides database specific to CT26 Mlh1^-/-